3. Genomic Testing: Unlocking New HR+ HER2- Breast Cancer Therapies

Today, we are speaking with Dr. Mia Levy, former Chief Medical Officer at Foundation Medicine. With nearly two decades of experience as a medical oncologist specializing in breast cancer, Dr. Levy is a nationally recognized leader in precision oncology and biomedical informatics. Before joining Foundation Medicine, she served as Director of the Cancer Center at Rush University Medical Center and System Vice President for Cancer Services at Rush System for Health. She has extensive expertise in developing data-driven systems to support decision-making in cancer care and research, including leading the development of My Cancer Genome, an international resource for guiding treatment decisions based on tumor genetics. We discuss some of the latest advancements in breast cancer treatment, including the role of PI3K pathway alterations and acquired alterations in ESR1 in identifying patients who may benefit from targeted therapies. We’ll explore how genomic testing is shaping the future of precision medicine and what these developments mean for both clinicians and patients.